Alzheimer’s disease and epilepsy are common nervous system diseases in older adults, and their incidence rates tend to increase with age. Patients with mild cognitive impairment and Alzheimer’s disease are more prone to have seizures. In patients older than 65 years, neurodegenerative conditions accounted for ~10% of all late-onset epilepsy cases, most of which are Alzheimer’s disease. Epilepsy and seizure can occur in the early and late stages of Alzheimer’s disease, leading to functional deterioration and behavioral alterations. Seizures promote amyloid-β and tau deposits, leading to neurodegenerative processes. Thus, there is a bi-directional association between Alzheimer’s disease and epilepsy. Epilepsy is a risk factor for Alzheimer’s disease and, in turn, Alzheimer’s disease is an independent risk factor for developing epilepsy in old age. Many studies have evaluated the shared pathogenesis and clinical relevance of Alzheimer’s disease and epilepsy. In this review, we discuss the clinical associations between Alzheimer’s disease and epilepsy, including their incidence, clinical features, and electroencephalogram abnormalities. Clinical studies of the two disorders in recent years are summarized, and new antiepileptic drugs used for treating Alzheimer’s disease are reviewed.

### Keywords
Alzheimer’s disease, epilepsy, cognitive, temporal lobe epilepsy, antiepileptic drugs

### Introduction

Alzheimer’s disease (AD) and epilepsy are common nervous system diseases in older adults, and their incidence rates tend to increase with age. Epilepsy is approximately three times more common in individuals aged 65 years and older (1). Patients with mild cognitive impairment (MCI) and AD are more prone to have seizures (2). Specifically, the incidence of hippocampus-related degenerative diseases, such as AD and temporal lobe epilepsy (TLE), is increasing, partly because the hippocampus is susceptible to toxic substances such as excitatory amino acids, resulting in neuronal dysfunction, cognitive impairment, and death (3). Late-onset epilepsy is mostly secondary to brain diseases such as stroke, tumor, and neurodegenerative diseases, and many of them are of unknown etiology (4). In patients older than 65 years, neurodegenerative conditions accounted for ~10% of all late-onset epilepsy cases, most of which are AD (5). Epilepsy and seizure can occur in the early and late stages of AD, leading to functional deterioration and behavioral alterations (2). Evidence from both experimental and human studies has proven the existence of an association between epilepsy and AD (6). Transgenic
mouse models with simulate familial AD can develop spontaneous epilepsy (7). Furthermore, seizures can lead to cognitive deficits, the trajectory of cognitive changes in patients with TLE differs from the pattern observed in healthy aging. Seizures also promote amyloid-β and tau deposits, leading to neurodegenerative processes (8). Thus, there is a bi-directional association between AD and epilepsy. Epilepsy is a risk factor for AD and, in turn, AD is an independent risk factor for developing epilepsy in old age (9). Many studies have evaluated the shared pathogenesis and clinical relevance of AD and epilepsy (5, 10, 11). In this review, we discuss the clinical associations between AD and epilepsy, including their incidence, clinical features, and electroencephalogram (EEG) abnormalities. Clinical studies of the two disorders in recent years are summarized (Table 1), and new antiepileptic drugs used for treating AD are reviewed.

Mechanistic evidences for co-morbidity of AD and epilepsy

The hippocampus shows similar pathological changes in patients with AD and individuals with epilepsy, such as loss of granulosa cells in the dentate gyrus, circuit reorganization, and damage to hippocampal neurons (22). The main pathological features of AD are amyloid β (Aβ) deposition outside neural cells and accumulation of hyperphosphorylated tau-protein in neurofibrillary tangles (23). These pathologies have also been observed in patients with TLE (24). In a study of 101 patients with TLE (aged 30–61 years) who underwent temporal lobectomy, 10 patients had Aβ plaques in brain samples (25). Tai et al. (26) performed pathological examinations on tissues from 33 patients aged 50–65 years who underwent temporal lobectomy for drug resistant TLE and found that 31 of the 33 patients (94%) had hyperphosphorylated tau. Hyperexcitability of nervous tissue is primarily responsible for increased seizure (27). Network hyperexcitability which induced by intracellular Aβ oligomers can occur in the early stages of AD and contribute to cognitive decline (28, 29). Recent studies have shown that presenilin 2 (PSEN2) knockout mice demonstrated early-life reductions in seizure threshold, and patients with PSEN gene variants also reported seizures (30). Furthermore, the increased tau pathology was associated with a greater decline in language learning, recall, and graded naming test scores (31). In patients with epilepsy, neurodegeneration occurs in the hippocampus, the temporal cortex, and the amygdala, with hippocampal sclerosis being the most characteristic structural change (32). Hippocampal sclerosis can cause neuronal loss and disruption of the balance between excitatory and inhibitory signaling in the sclerotic area, resulting in highly synchronous abnormal neuronal discharge (33). The hippocampus is an important part of the limbic system that plays a central role in memory function and is a site of early neurofibrillary tangle development (34). Therefore, pathological changes in the hippocampus may represent a link between AD and epilepsy.

Other neurochemical changes associated with both AD and epilepsy include GABAergic (35) and glutamatergic alterations (36), Aβ and tau protein deposition (37), neuroinflammation (10), and damage to the noradrenergic nervous system in the locus coeruleus (38) (Figure 1).

Clinical evidence of AD and epilepsy co-morbidity

AD is an important cause of senile epilepsy. Increased AD duration is associated with a higher risk of epilepsy (39). In addition, the risk of epilepsy in patients with AD is 10 times higher than that of individuals without AD in people over the age of 65 years (40). Horvath et al. (13) conducted a 3-year prospective follow-up study that included yearly cognitive assessments on 38 patients with AD and 20 healthy individuals and found that subclinical epileptiform discharges were recorded more frequently in patients with AD (54%) than in healthy, elderly (25%) individuals. Subclinical epileptiform activity was also observed in patients with amnestic mild cognitive impairment (aMCI) or early AD (28). Patients with familial early-onset AD have a higher risk of having seizures (41). Haoudy et al. (42) studied 25 patients with early onset AD and positive cerebrospinal fluid AD biomarkers. Based on epilepsy expert consultation and EEG examination, the results showed that 10 (40%) of these patients had epilepsy.

Epilepsy may play a causal role in AD development. In some cases, seizures may begin concurrently with onset of cognitive decline or even precede onset of AD (28). In AD patients, increased susceptibility to seizures and silent epileptiform activity due to disruption of the excitatory /inhibitory balance occur much earlier than cognitive impairment. The increase of epileptiform activity may be the main pathology in the early stage, which directly contributes to cognitive impairment (43). In a postmortem study (44), chronic epilepsy was associated with increased tau neurofibrillary tangles at mid-braak stages in patients aged 40–65 years. AD is a chronic, progressive disease that includes MCI and aMCI. Because the typical symptoms of AD may occur only after repeated seizures for several years, increasing numbers of studies have evaluated cognition in epilepsy. In one study (19), 13 out of 24 patients with late onset epilepsy of unknown etiology (LOEU) who were followed for 5.1 years had MCI. Most LOEU patients had an MCI status during seizures (59%) (45). The use of various antiepileptic drugs in the successful treatment of cognitive impairment in patients with AD provides an additional link between epilepsy and AD (46).
## TABLE 1 Summary of clinical studies of AD and epilepsy.

| Reference      | Study type                                                                 | Sample size (n) | Age (years) | Epilepsy type or seizure form | Follow up time | Results                                                                                                                                  | Study limitations                                                                                       |
|---------------|-----------------------------------------------------------------------------|-----------------|-------------|-------------------------------|----------------|-----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| Lam et al. (12)| A cross-sectional study of epileptiform abnormalities in patients with AD   | 99              | 50–90       | Epileptiform discharge         | No             | Epileptiform abnormalities occurred in 53% of patients with early-stage AD plus late-onset epilepsy related to AD | The sample size was small, and the sample had selection bias                                           |
| Horvath et al. (13)| A prospective study of subclinical epileptiform activity accelerating the progression of AD | 72              | 60–84       | Epileptiform discharge         | 3 years        | Subclinical epileptiform discharges were recorded in 54% of AD patients                                                              | EEG was not performed at the end of follow-up                                                            |
| Horvath et al. (14)| A retrospective and prospective study on the prevalence of epilepsy in AD using ambulatory EEG | 42              | 70–84       | Focal seizures                 | No             | Seizures confirmed by EEG accounted for 24%                                                                                           | The sample size was small, and there was no distinction between early-onset and late-onset AD          |
| Arnaudi et al. (15)| To retrospectively study the prevalence of epilepsy in AD                  | 1,645           | 60–81       | Generalized seizures, Focal seizures | 1 year         | The prevalence of epilepsy was 1.82% for AD                                                                                           | Retrospective data collection, lack of biomarkers for brain amyloidosis and tau protein                  |
| Difrancesco et al. (11)| A retrospective, observational, single center study on the prevalence of epilepsy in adults with presymptomatic AD | 23              | 55–82       | Generalized seizures, Focal seizures | No             | In patients with AD, the prevalence of epilepsy before cognitive decline was 17.1 times that of the reference population              | Retrospective data collection, samples were selected from a single center                                |
| Tedrus et al. (16)| Clinical study evaluating cognitive ability and its correlation with QEEG in patients with epilepsy | 120             | 32–59       | No                            | No             | Adult patients with epilepsy had cognitive impairment that was significantly correlated with QEEG                                   | Small sample size and single sample source                                                               |
| Voglein et al. (17)| A prospective study on the recurrence rate of epilepsy in AD                | 20,745          | 60–85       | No                            | 7.5 months     | In AD patients, the risk of recurrence of seizures within 7.5 months was 70.4%                                                      | The influence of antiepileptic drugs on epilepsy recurrence was not analyzed, and the withdrawal rate was about 56% |
| Reyes et al. (18)| A cross-sectional study describing the nature and prevalence of cognitive impairment in TLE | 217             | 55–80       | Senile TLE                    | No             | 60% of older adults with TLE also had MCI                                                                                             | There was no longitudinal data or information on AD progression, and the sample representation was insufficient |
| Costa et al. (19)| A retrospective study on the risk stratification of cognitive decline in LOEU | 24              | 59–73       | LOEU                          | 5.1 years      | During the follow-up of more than 5.1 years, 4 of 24 patients with LOEU developed AD                                                 | The sample size was small, and AD could not be accurately diagnosed according to stratification          |
| Schnier et al. (20)| A nationwide cohort study of epilepsy and dementia events                  | 563,151         | >60         | No classification             | 10 years       | The risk of AD in patients with epilepsy was 1.6 times higher than that in the control group                               | Miscategorization bias may exist from the case definition for epilepsy                                    |
| Liguori et al. (21)| Prospective and observational study on cognitive performance of patients with LOEU | 58              | 50–75       | LOEU                          | 1 year         | MMSE and memory scores decreased significantly in LOEU at follow-up (12 months later)                                              | The sample size was small                                                                               |
Cognitive impairment in epilepsy

Prevalence of cognitive impairment in epilepsy

In the UK, the prevalence of AD among patients with epilepsy is about 8% (47). In a population-based prospective study of seizures in adults aged > 17 years, Forsgren et al. (48) collected data of 563 patients with possible seizures in 34 months and found that seven cases were caused by AD (incidence 4%). In a cohort of 177 patients with newly diagnosed clinically with probable AD, 12 (6.8%) had a history of epilepsy and/or were using antiepileptic drugs at the time of diagnosis (49). Studies (50) have shown that 11% of adult patients with seizures suffer from AD. In a 10-year follow-up study, the 10-year cumulative incidence of dementia (including AD, vascular dementia) in patients with LOEU was 22% (51). To assess the relationship between epilepsy and dementia (including AD, vascular dementia) risk in Taiwan, Tsai et al. (52) conducted a retrospective cohort study that included 675 patients (age ≥ 50 years) with epilepsy and 2,025 age-matched control subjects. Their results showed that individuals in the epilepsy cohort were at significantly increased risk of dementia compared with individuals in the control cohort. The risk of dementia in patients with epilepsy was also evaluated in the Framingham Heart Study (53). The study included follow-up information for 4,906 participants with epilepsy over the age of 65 years, and identified 51 cases of sporadic dementia (84% with AD type) in 43 patients with epilepsy and 129 controls without epilepsy. A study (54) of 247 untreated patients with newly diagnosed epilepsy showed that 49.4% of patients had impaired attention and executive function, and 47.8% had memory impairment.

Clinical characteristics of cognitive impairment in epilepsy

Patients with epilepsy, especially late-onset epilepsy, often have cognitive impairment. Most seizure-related cognitive problems are affected by a variety of interrelated factors, including early age of seizure onset, seizure frequency, intensity and duration, and antiepileptic drug treatment (55). For example, patients diagnosed with LOEU show a significant decline in cognitive ability, unrelated to antiepileptic drug treatment, 12 months after diagnosis (21). In a study that assessed 38 elderly adults with epilepsy and 29 healthy controls, a comprehensive neuropsychological battery showed that the group with epilepsy had lower Mini-Mental State Examination (MMSE) and Dementia Rating Scale (DRS) total scores, performed worse on the attention and memory subscales of the DRS, and had poorer composite domain scores for verbal memory, visual memory, executive function, language, and processing speed when compared with controls (56). Wang et al. (57) studied 257 adult patients with epilepsy and observed that the overall cognitive function of patients with epilepsy was lower than the reference range for the Montreal Cognitive Assessment (MoCA) and clinical memory scale. Reyes et al. (18) studied 71 patients with TLE, 77 patients with aMCI, and 69 healthy
controls. They found that 43 patients with TLE (60%) met the TLE-MCI standard and showed obvious memory and language defects. Subgroup analysis by age of seizure onset revealed that 63% of patients with early seizure onset (<50 years old) and 56% of patients with late seizure onset (≥50 years old) met the TLE-MCI standard. Patients with TLE-MCI showed greater language defects, while patients with aMCI forgot information more rapidly. Taylor et al. (58) found that memory and psychomotor speed were the most affected areas of cognitive function in patients with epilepsy.

Memory, processing speed, and higher executive function are the cognitive functions most prone to change within 12 months in newly diagnosed patients with epilepsy (59). For examples, when patterns of cortical atrophy and cognitive impairment were analyzed in 73 elderly patients with TLE (>55 years), 79 patients with aMCI, and 70 healthy controls were studied (60), results showed that the elderly patients with TLE exhibited medial temporal lobe atrophy similar to that observed in patients with aMCI. The TLE and aMCI groups also showed significant memory and language impairment when compared to the healthy control group. The association between medial temporal lobe atrophy and cognitive impairment in elderly people with TLE and aMCI demonstrates the risk of cognitive impairment associated with epilepsy. Johnson et al. (61) studied the relationship between late-onset epilepsy (LOE) and changes in cognitive ability over a 25 year period and found that LOE was associated with rapid declines in cognition, verbal memory, executive function, and word fluency.

EEG characteristics of cognitive impairment in epilepsy

Interictal epileptic discharge (IED) are the EEG signs of epilepsies between seizures (62). Some cognitive loss might evolve in some epilepsies and patients if many and long term (63). Interictal activity results in significant changes in cognitive function, especially learning and memory (64). In patients with long-term TLE, the occurrence of IED is strongly related to cognitive impairment, and the most obvious is frontal lobe function (65). Liu et al. (62) performed EEG examinations and global cognitive assessments on 167 adult patients with and without epilepsy and showed that verbal fluency and language scores were reduced in patients with IED. They also found that sleep-phase IEDs were associated with lower cognitive performance. Interictal spike, especially if frequent and extensive, can impair cognitive abilities through interference with waking learning and memory, as well as memory consolidation, during sleep (66).

Moreover, Ung et al. (67) found that interictal epileptic activity outside the left hemispheric seizure onset zone impacted memory encoding, recall, and retrieval, while those inside the seizure onset zone did not. Hippocampal interictal epileptiform activity disrupted memory maintenance and retrieval, but not encoding cognition in humans (68). Horak et al. (69) also collected data of 80 patients with epilepsy who participated in the delayed free recall task while undergoing intracranial EEG monitoring and found that IED in the inferior-temporal, medial-temporal, and parietal areas significantly affected memory.

Frequent seizures can reduce the power and frequency of theta waves (70). Quantitative EEG (QEEG) can be used to objectively evaluate the power of radio waves that reflect cognition. The association between epilepsy and QEEG was studied in 80 adult patients with epilepsy and 40 healthy controls. The results showed that adult patients with epilepsy had cognitive impairment that significantly correlated with QEEG changes. Thus, QEEG may aid in understanding the pathophysiology of epilepsy and serve as an early marker of the cognitive changes that occur in epilepsy (16). Further evidence of the association between QEEG and cognitive changes in epilepsy is provided by Elsheif et al. (71), who administered cognitive tests and performed QEEG evaluation of EEG markers (median frequency, peak frequency, and alpha-to-theta ratio) in 45 patients with TLE. Researchers showed a strong negative correlation between cognition in patients with TLE and measured EEG markers. Thus, QEEG of these three EEG markers may be used to identify early cognitive impairment in patients with epilepsy.

Epilepsy and seizure in AD

Prevalence of epilepsy and seizure in AD

Epidemiological data on epilepsy in AD is limited, likely because neurodegeneration begins a few years prior to the emergence of clinical symptoms, and epilepsy may have been present in the pre-symptomatic stage of AD (15). The estimated prevalence of epilepsy in patients with dementia (including AD, vascular dementia, Lewy body disease) is about 5% (72). However, a recent prospective cohort study (73) with large sample size, long follow-up, and carefully characterized evaluations estimated the overall incidence of seizures in AD at ~1 per 200 person-years of observation, suggesting relatively lower frequencies than those reported in other studies. Vossel et al. (74) found that 42.4% of patients with AD exhibited epileptic activity compared with 10.5% in the control group. Furthermore, the overall cognitive ability of patients with epileptic activity decreased faster than that in the control group. Zelano et al. (75) assessed the risk of epilepsy in patients with AD. The results showed that the risk of epilepsy at 5 and 10 years after onset of AD was 2.1% and 4.0%, while that in the control group was 0.8 and 1.6%, respectively. However, Mahamud et al. (76) estimated that the risk of epilepsy diagnosis in the 5
years following a first, unprovoked seizure in patients with AD was 32%, compared to 31% in the control group. Cognitively asymptomatic individuals who harbor pathogenic autosomal dominant AD mutations were more likely to have seizures (77).

Clinical characteristics of seizure in AD

Seizures may be particularly difficult to diagnose in patients with AD, as most reports of seizure symptoms in AD patients are provided by caregivers. It may be difficult for caregivers to describe seizure symptoms and to distinguish these symptoms from common manifestations of AD (such as hallucinations and delusions) (40). TLE may be an early feature of sporadic AD (78). Among patients with aMCI or AD with epilepsy, complex partial seizures are most common, and more than half of these seizures are non-convulsive (28). A study (46) showed that generalized tonic-clonic seizures occurred in 15–40% of patients with advanced AD complicated with epilepsy, and 70% of seizures in these patients were focal. Horváth et al. (14) analyzed the characteristics of 18 seizures in 10 patients with AD and found that 11% of the seizures were generalized tonic-clonic, 72% were focal seizures with impaired awareness, and 55% were non-motor seizures. Haoudy et al. (42) investigated 40 patients with early onset AD (EOAD) and found that the most common seizure types were tonic-clonic (25%), typical temporal seizures (25%), myoclonic (25%), focal extra-temporal (8%), and other seizure types (17%). Subclinical epileptiform activity in patients with AD has also been associated with cognitive ability (79). Vossel et al. (74) found that patients with AD and subclinical epileptiform activity have a faster decline in overall cognitive ability, as evidenced by a decrease of 3.9 points per year in their MMSE score. This is compared to the 1.6 points per year decrease observed in patients with AD without epileptiform activity.

Costa et al. (80) showed that the incidence rate of late-onset cryptogenic epilepsy in patients with advanced AD was associated with higher concentrations of AD markers in CSF. They retrospectively selected and studied 13 patients who met the diagnostic criteria for MCI. All 13 patients also met the criteria for clinical diagnosis of epilepsy prior to MCI diagnosis. Interestingly, epilepsy appeared 4–7 years earlier than AD. This phenomenon was termed epileptic prodromal AD, and researchers suggested that epileptic prodromal AD is an epileptic variant of AD. Furthermore, they suggested that the spectrum of AD should be extended to include epilepsy variants. In summary, epilepsy should be used as a phenotypic marker of AD (78).

EEG characteristics of seizure in AD

Focal seizures in AD may be difficult to identify and may not be detected by surface EEG electrodes that only detect cortical activity (81). In patients with AD, IED was usually detected in electrodes around the frontotemporal and temporal lobe brain regions (78). Vossel et al. (28) found temporal epileptiform abnormalities were the commonest finding, although frontal and generalized discharges were also seen. The results were consistent with Sarkis’s study results (82).

Because non-convulsive seizures may be masked by cognitive impairment, detection of epileptic-like activity may require long-term EEG monitoring (83). Long-term EEG recording, including during sleep, may result in a higher diagnostic rate (84). In a preliminary study (85), EEG abnormalities during sleep were associated with cerebrospinal fluid biomarkers, particularly hyperphosphorylated tau protein levels, suggesting the presence of preclinical AD. Horváth et al. (14) recorded electric ictal patterns twice during a recording period in 2 of 10 patients with AD, and clinically identified seizures in 8 of the 10 patients with AD using ambulatory EEG. Yu et al. (86) summarized the results of several research groups and found that epileptiform discharges, especially those with the specific characteristics of frequent, small spikes, temporal intermittent rhythmic delta activities, and paroxysmal slow wave events recorded using long-term scalp EEG, provided sufficient sensitivity and specificity for detecting the epileptogenic nature of AD. Horváth et al. (13) found that epileptiform discharges were associated with lower memory scores. Lam et al. (12) found that epileptiform discharges tended to occur during periods of wakefulness and during rapid eye movement sleep (REM sleep). Frequent spikes were particularly associated with epileptiform EEG and may serve as markers of hyperexcitability in AD.

The sensitivity and daily distribution of epileptiform discharges are different during different periods throughout the day. For example, Horváth et al. (87) found that EEG epileptiform discharges were more likely to be recorded between 8:00 and 16:00, while 82% of epileptiform discharges in sleep occurred during non-REM sleep. Moreover, AD progression was related to the high recurrence of seizures. Voglein et al. (17) investigated 20,745 individuals from the National Alzheimer’s Coordinating Center and found that the risk of epilepsy recurrence within the following 7.5-month period was 70.4% in patients with AD. Furthermore, seizure prevalence increased with increasing duration of AD.

Treatment

The close relationship between epilepsy and AD indicates that both epilepsy and AD require active intervention. Antiepileptic drugs (AEDs) improve cognitive symptoms and have antiepileptic effects (88). Use of AEDs can directly inhibit seizures and hyperexcitability, which may reduce Aβ accumulation (89). However, because cognitive function is particularly susceptible to decline in patients with AD, the possible neurocognitive effects of these drugs must be
| References | Study type | Sample size (n) | Age (years) | Antiepileptic drugs | Follow up time | Results | Defects (limitations) |
|------------|------------|----------------|-------------|---------------------|----------------|---------|----------------------|
| Schoenberg et al. (107) | Effects of LEV on cognition, emotion, and balance in healthy, elderly individuals | 20 | 65–80 | LEV | 5 weeks | LEV had no adverse effect on cognition or balance in the elderly with epilepsy | The study duration was relatively short, and the sample size was small |
| Howard et al. (108) | Clinical trial of 2 different doses of minocycline and placebo in patients with mild AD | 544 | 68–83 | Minocycline | 24 months | Minocycline did not delay the progression of cognitive or functional impairment in patients with mild AD within 2 years | Biomarkers were not used to confirm the diagnosis of AD and subject compliance was poor |
| Li et al. (109) | Effect of LCM on cognitive function and mental status in patients with epilepsy | 251 | Not limited | LCM | Not reported | LCM had limited effects on cognitive and emotional states | Number of references was limited |
| Liguori et al. (110) | To compare the cognitive side effects of LCM and carbamazepine | 16 | 50–68 | LCM | Not reported | LCM showed an increase in the EpiTrack score used to measure cognitive ability during follow-up | The sample size was very small, and the data was not obtained systematically |
| Lattanzi et al. (111) | Adjunctive BRV in older patients with focal seizures | 1,029 | ≥65 | BRV | 12 months | BRV was efficacious, had good tolerability, and no unexpected safety signals emerged | Retrospective and network study analysis of PER is limited by the size of the elderly subgroup |
| Leppik et al. (112) | Effects of PER in elderly patients with epilepsy | 28 | ≥65 | PER | 23 weeks | Efficacy and adverse event rates were found to be consistent with the adult population | Analysis of PER is limited by the size of the elderly subgroup |
| Sarkis et al. (103) | Tolerability of ZNS in elderly patients with seizures | 39 | ≥60 | ZNS | 23 months | ZNS and LCM had similar retention rates, 4 discontinuations due to cognitive or behavioral side effects | Side effects were retrieved from the chart rather than reported systematically by the patients |
| Pohllmann-Eden et al. (113) | Comparative effectiveness of LEV, VPA and CBZ among elderly patients with epilepsy | 308 | ≥60 | LEV | 52 weeks | LEV may be a suitable option for patients aged ≥60 years with epilepsy | Results are exploratory, since subgroup analysis by age was not powered |
| Massaeus et al. (114) | LEV alters oscillatory connectivity in AD | 12 | 50–90 | LEV | 3 weeks | Decreases in coherence in the delta band (1–3.99 Hz) suggested a beneficial effect of LEV for patients with AD | There were no significant changes in cognitive performance after this single dose administration |
considered when prescribing AEDs for AD (90). Use of AEDs may increase the risk of developing AD (91).

Elderly individuals are at higher risk for developing chronic diseases and often take a variety of oral medications. Thus, drug-drug interactions that alter drug metabolism and/or bioavailability must be considered when prescribing AEDs in elderly individuals. These types of drug-drug interactions may induce a variety of adverse effects that aggravate cognitive impairment (92). For example, benzodiazepines may enhance GABA secretion by astrocytes, resulting in an increased risk for developing AD (93, 94). Therefore, benzodiazepines are not recommended for treatment of seizures in AD patients. Valproic acid (VPA) should also be avoided, because it may lead to cognitive decline (95). A retrospective (96) analysis of ten antiepileptic drugs prescribed to elderly, showed that cognitive adverse effects are common in patients on topiramate (TPM) followed by those on zonisamide (ZNS) and gabapentin (GBP). A meta-analysis (97) reported that LTG was associated with a lower probability of seizure freedom than LEV and had a limited effect on cognition in older people with epilepsy. However, Liu et al. (98) performed a randomized controlled trial on drug intervention that indicated that LEV seemed to improve cognition, whereas phenobarbital and LTG could worsen cognition. Additional studies are needed to further characterize treatment of AD-related epilepsy with LTG.

LEV is a novel antiepileptic drug that has the ability to reverse cognitive impairment (99). Vossel et al. (100) studied the effect of LEV on cognitive ability in AD patients with and without epileptic activity and found that LEV improved spatial memory performance and executive ability in patients with AD with epileptic activity. This effect may be due to reduced AD-associated network hyperexcitability. Brivaracetam (BRV) is an antiepileptic drug that was approved by the FDA in 2013 for the treatment of partial seizures. Brodie et al. (101) followed up the tolerability, safety, and efficacy of BRV for adjunctive treatment of focal (partial-onset) seizures in patients aged ≥65 years. Thirty-two cases were included and the results showed that BRV was effective with no significant impact on cognition. In animal experiments, BRV reversed memory deficits in a mouse model of AD (102). A retrospective analysis of 71 patients with epilepsy (>60 years old) who were treated with lacosamide (LCM) showed that 60% of patients continued to take LCM at their 12-month follow-up visit, and no patients discontinued taking LCM due to cognitive issues (103). Perampanel (PER) is a third-generation antiepileptic non-selective AMPA receptor antagonist used to treat patients over the age of 12 years who have epilepsy. Ahn et al. (104) recruited 17 patients with epilepsy and treated them with PER for 6 months. In this cohort, PER did not induce cognitive decline. Lattanzi et al. (105) reviewed and analyzed the adverse events experienced by elderly patients with epilepsy who took PER at 12 different Italian epilepsy centers. The results showed that the common adverse events in elderly individuals taking PER were dizziness, irritability, and drowsiness. Cognitive decline was not common. Rohracher et al. (106) conducted a critical narrative review on the use of new AEDs in elderly patients with epilepsy. The results showed that PER and LCM had the lowest interaction risk and were considered first-line drugs for epilepsy treatment in elderly patients. Other studies of these AEDs are summarized in Table 2.

Conclusion and future directions

Studies have shown that epilepsy and AD share a common underlying pathology. Seizures, especially generalized tonic-clonic and complex partial/non-convulsive ones are typically associated with a transitory cognitive impairment, even in case of incidental and single seizures. A thorough investigation of the risk and etiology of recurrent seizures is needed. Early identification of epilepsy in patients with AD and in the AD prodromal stage, through various diagnostic techniques (including EEG), is critical. Seizures related to AD may precede or coincide with the onset of the cognitive decline. Early identification of non-convulsive seizures and the recognition of epileptiform EEG activity is of crucial importance for patient outcome. The new generation of AEDs is more suitable for treatment of elderly patients with epilepsy and neurodegenerative diseases due to their superior pharmacokinetic characteristics. Timing of intervention is critical. Most research on hyperexcitability in AD has focused on Aβ and Tau, but other factors, such as presenilin 2 (PSEN2), may contribute to hyperexcitability in AD. Future studies should focus on multiple potential mechanisms of hyperactivity in AD, as this may lead to further characterization of the shared pathogenesis of AD and epilepsy and may allow for identification of novel therapies.

Author contributions

JW and SX searched the literature. WC and YZ conducted literature review and analysis. DZ and SC wrote original draft. XC did review and editing. XL was responsible for supervision. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the scientific research plan of the Affiliated People's Hospital of Jiangsu University (Y201933).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Banerjee PN, Filippi D, Allen Hauser W. The descriptive epidemiology of epilepsy—a review. Epilepsy Res. (2009) 85:31–45. doi: 10.1016/j.eplepsyres.2009.03.003
2. Amatniek JC, Hauser WA, DeCastillo-Castaneda C, Jacobs DM, Marder K, Bell K, et al. Incidence and predictors of seizures in patients with Alzheimer’s disease. Epilepsia. (2006) 47:867–72. doi: 10.1111/j.1528-1167.2006.00554.x
3. Sen A, Capelli V, Husain M. Cognition and dementia in older patients with epilepsy. Brain. (2018) 141:1592–608. doi: 10.1093/brain/awy022
4. Neri S, Mastroani G, Gardella E, Aguglia U, Rubboli G. Epilepsy in neurodegenerative diseases. Epileptic Disord. (2022) 24:349–73. doi: 10.1684/epd.2021.1466
5. Friedman D, Honig LS, Scarmeas N. Seizures and epilepsy in Alzheimer’s disease: a review. Epilepsy Res. (2009) 85:31–45. doi: 10.1016/j.eplepsyres.2009.03.003
6. Bakker A, Kraus GL, Albert MS, Speck CL, Jones LR, Stark CE, et al. Reduction of hippocampal hyperactivity improves cognitive impairment in amnestic mild cognitive impairment. Neuron. (2012) 74:467–74. doi: 10.1016/j.neuron.2012.03.023
7. Paudel YN, Angelopoulou E, Piperi C, Othman I, Shaikh MF. Revisting tau in epileptic brain and chronic traumatic encephalopathy. Neurology. (2020) 95:e1686–e93. doi: 10.1212/WNL.0000000000010358
8. Giorgi FS, Saccaro LF, Bugioni F, Fornai F. Epilepsy and Alzheimer’s disease: potential mechanisms for an association. Alzheimer’s Dis. Rep. (2021) 5:21–5. doi: 10.3233/ADR-200286
9. Altuna M, Olmedo-Saura G, Carmona-Iragui M, Fortea J. Mechanisms involved in epileptogenesis in Alzheimer’s disease and their therapeutic implications. Int J Mol Sci. (2022) 23:4307. doi: 10.3390/ijms23084307
10. Giorgi FS, Saccaro LF, Bugioni F, Fornai F. Epilepsy and Alzheimer’s disease: potential mechanisms for an association. Brain Res Bull. (2020) 160:107–20. doi: 10.1016/j.brainresbull.2020.04.009
11. DiFrancesco JC, Tremolizzo L, Polonia V, Giussani G, Bianchi E, Franchi C, et al. Adult-onset epilepsy in presymptomatic Alzheimer’s disease: a retrospective study. J Alzheimers Dis Rep. (2021) 5:243–61. doi: 10.3233/JADR-200286
12. Beckman M, Knox K, Koneval Z, Lee SE, Naasan G, et al. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. (2013) 70:1158–66. doi: 10.1001/jamaneurol.2013.136
13. Fernández-Pérez EJ, Munoz B, Bascunan DA, Peters C, Rufio-Lepe NO, Espinoza MP, et al. Synaptic dysregulation and hyperexcitability induced by intracellular amyloid beta oligomers. Aging Cell. (2021) 20:e13455. doi: 10.1111/acel.13455
14. Beckman M, Knox K, Koneval Z, Smith C, Jayadev S, Barker-Halaci M. Loss of presenilin 2 age-dependently alters susceptibility to acute seizures and kindling acquisition. Neurobiol Dis. (2016) 136:104719. doi: 10.1016/j.nbd.2019.104719
15. Teixeira CM, Pallas-Bazarrar N, Bolos M, Terreros-Roncal J, Avila J, Llorens-Martín M. Untold new beginnings: adult hippocampal neurogenesis and Alzheimer’s disease. J Alzheimers Dis. (2018) 64:5497–505. doi: 10.3233/JAD-179918
16. Scharfman HE. Alzheimer’s disease and epilepsy: insight from animal models. Future Neurol. (2012) 7:177–92. doi: 10.2217/fnl.12.8
17. Kim S, Nam Y, Jeong YO, Park HH, Lee SK, Shin SJ, et al. Topographical visualization of the reciprocal projection between the medial septum and the hippocampus in the 5xFAD mouse model of Alzheimer’s disease. Int J Mol Sci. (2019) 20:3992. doi: 10.3390/ijms20163992
18. Eissa H, Peyton L, Hasan W, Leon BE, Choi DS. Implication of adult hippocampal neurogenesis in Alzheimer’s disease and potential therapeutic approaches. Cells. (2022) 11:286. doi: 10.3390/cells11020286
19. Sakimoto Y, Oo PM, Goshima M, Kaniehisa I, Tsukada Y, Mitsushima D. Significance of gabapentin receptor for cognitive function and hippocampal pathology. Int J Mol Sci. (2021) 22:3456. doi: 10.3390/ijms223456
20. Dejakasaya H, Kwan P, Jones NC. Astrocyte and glutamate involvement in the pathogenesis of epilepsy in Alzheimer’s disease. Epilepsia. (2021) 62:1485–93. doi: 10.1111/epilepsia
Zhang et al. (2011) 134:2969–81. doi: 10.1093/brain/awr209

ACS Chem Neurosci.

Tau related pathways as a connecting link between epilepsy and alzheimer's disease.

and epilepsy: possible role of the noradrenergic nervous system.

Frontiers in Neurology

viewed characteristics.

Epilepsia.

Dement Geriatr Cogn Disord.

diagnosis of probable alzheimer's disease.

53(Suppl 1):61–6. doi: 10.1111/j.1528-1167.2012.03476.x

clinical and epidemiological data.

Epilepsy Curr.

Systematic review of coexistent epileptic seizures and alzheimer's disease: incidence

87. doi: 10.18632/aging.202299

Epilepsy Behav.

73:61–7. doi: 10.1016/j.neurobiolaging.2018.09.006

Epilepsy Behav.

58:368–7. doi: 10.1111/epi.13633

Epilepsy Behav. (2016) 62:297–303. doi: 10.1016/j.yebeh.2016.07.101

Epilepsy Behav. (2016) 58:962–72. doi: 10.1111/epi.13744

Epilepsy Behav. (2012) 54:700–7. doi: 10.1111/epi.12045

Epilepsy Behav. (2017) 55:1282–

Epilepsia.

al. Incidence and impact of subclinical epileptiform activity in alzheimer's disease.

Brain.

Alzheimer's disease.

Front Mol Neurosci.

68. Kleen JK, Scott RC, Holmes GL, Roberts DW, Rundle MM, Testorf M, et al. Hippocampal interictal epileptiform activity disrupts cognition in humans. Neurology. (2013) 81:18–24. doi: 10.1212/WM.0b013e318297e7e9

69. Horak PC, Menesheinler S, Song Y, Testorf ME, Kahana MJ, Viles WD, et al. Interictal epileptiform discharges impair word recall in multiple brain areas. Epilepsy Res. (2015) 115:51–8. doi: 10.1016/j.eplepsyres.2015.06.009

61. Johnson EL, Krauss GL, Walker KA, Brandt J, Kucharska-Newton A, Mosley TH Jr, et al. Late-onset epilepsy and 25-year cognitive change: the atherosclerosis risk in communities (arc) study. Epilepsia. (2020) 61:1764–73. doi: 10.1111/epi.16616

60. Kaestner E, Reyes A, Chen A, Rao J, Macari AC, Choi JY, et al. Atrophy and cognitive profiles in older adults with temporal lobe epilepsy are similar to mild cognitive impairment. Brain. (2021) 144:236–50. doi: 10.1093/brain/awaa387

62. Liu YY, Shi T, Yin WN, Ren ZT, Deng YL, Chen SD. Interictal epileptiform discharges were associated with poorer cognitive performance in adult epileptic patients. Epilepsie Res. (2016) 128:1–5. doi: 10.1016/j.eplepsres.2016.09.022

63. Stafstrom CE, Carmant L. Seizures and epilepsy: an overview for neuroscientists. Cold Spring Harb Perspect Med. (2015) 7:a022426. doi: 10.1101/cshperspect.a022426

64. Landi S, Petrucco L, Sicc F, Ratto GM. Transient cognitive impairment in epilepsy. Front Mol Neurosci. (2018) 11:458. doi: 10.3389/fnmol.2018.00458

65. Dinkelacker V, Xaver U, Baulac M, Samson S, Dupont S. Interictal epileptiform discharges correlates with global and frontal cognitive dysfunction in temporal lobe epilepsy. Epilepsy Behav. (2016) 62:197–203. doi: 10.1016/j.yebeh.2016.07.009

66. Holmes GL. Interictal spikes as an EEG biomarker of cognitive impairment. J Clin Neurophysiol. (2022) 39:101–12. doi: 10.1097/NCP.0000000000000728

67. Ung H, Cazares C, Nanivadekar A, Kimi L, Wagenau J, Becker D, et al. Interictal epileptiform activity outside the seizure onset zone impacts cognition. Brain. (2017) 140:215–67. doi: 10.1093/brain/awx143

68. Kleen JK, Scott RC, Holmes GL, Roberts DW, Rundle MM, Testorf M, et al. Hippocampal interictal epileptiform activity disrupts cognition in humans. Neurology. (2013) 81:18–24. doi: 10.1212/WM.0b013e318297e7e9

69. Horak PC, Menesheinler S, Song Y, Testorf ME, Kahana MJ, Viles WD, et al. Interictal epileptiform discharges impair word recall in multiple brain areas. Epilepsy Res. (2015) 115:51–8. doi: 10.1016/j.eplepsyres.2015.06.009

70. Loughman A, Seneviratne U, Bowden SC, D’Souza WJ. Epilepsy beyond seizures predicting enduring cognitive dysfunction in genetic generalized epilepsies. Epilepsie. Behav. (2016) 62:297–303. doi: 10.1016/j.yebeh.2016.07.010

71. Elsherif M, Esmael A. Hippocampal atrophy and quantitative EEG markers in mild cognitive impairment in temporal lobe epilepsy versus extra-temporal lobe epilepsy. Neurosci. Lett. (2012) 439:1957–86. doi: 10.1016/j.neulet.2012.01.0545-0

72. Subota A, Pham T, Jette N, Sauro K, Lorenzetti D, Holroyd-Leduc J. The association between dementia and epilepsy: a systematic review and meta-analysis. Epilepsia. (2017) 58:962–72. doi: 10.1111/epi.13744

73. Iruzarry MC, Jin S, He F, Emond JA, Raman R, Thomas RG, et al. Incidence of new-onset seizures in mild to moderate alzheimer disease. Arch Neurol. (2012) 69:368–72. doi: 10.1001/archneur.2011.830

74. Vossel KA, Ranasinghe KG, Beagle AJ, Mizuiri D, Hotoloy-Leduc J. The somatic comorbidity of epilepsy: a weighty but often unrecognized burden. Epilepsia. (2012) 53:1282–93. doi: 10.1111/j.1528-1167.2012.03328.x

75. Zelano J, Brigo F, Garcia-Patek S. Increased risk of epilepsy in patients registered in the Swedish dementia registry. Eur J Neurol. (2020) 27:129–

35. doi: 10.1111/ejnn.14043

76. Mahamud Z, Mononen CP, Brigo F, Garcia-Patek S, Zelano J. Risk of epilepsy diagnosis after a first unprovoked seizure in dementia. Seizure. (2020) 82:118–24. doi: 10.1016/j.seizure.2020.09.001

77. Voglein J, Noachast S, McDade E, Quaid KA, Salloway S, Ghetti B, et al. Seizures as an early symptom of autosomal dominant alzheimer's disease. Neurobiol Aging. (2019) 76:18–23. doi: 10.1016/j.neurobiolaging.2018.11.022

78. Cretin B, Sellal F, Phlipps N, Bouguies O, Di Bitonto L, Martin-Huynadi C, et al. Epileptic prodromal alzheimer's disease, a retrospective study of 13 new cases: expanding the spectrum of alzheimer's disease to an epileptic variant? J Alzheimers Dis. (2016) 52:1215–33. doi: 10.3233/JAD-150996

79. Ranaasinghe KG, Kudo K, Hinkley L, Beagle A, Mizuiri D, Hotoloy-Leduc J. The association between dementia and epilepsy: a systematic review and meta-analysis. Epilepsia. (2012) 53:2040–5. doi: 10.1111/j.1528-1167.2012.03434.x

80. Costa C, Romoli M, Liguori C, Farotti L, Eusibili P, Bedetti C, et al. Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology. Neurobiol Aging. (2019) 73:61–7. doi: 10.1016/j.neurobiolaging.2019.08.006

81. Lam AD, Deck G, Goldman A, Eskander EN, Noebels J, Cole AJ. Silent hippocampal seizures and spikes identified by foramen ovale electrodes in alzheimer's disease. Nat Med. (2017) 23:678–80. doi: 10.1038/nm.4330

82. Sarkis RA, Dickerson BC, Cole AJ, Chemali ZN. Clinical and neurophysiologic characteristics of unprovoked seizures in patients
Gallardo Gudino LR, Mendoza-Torreblanca JG, et al. Levetiracetam reduced synaptic plasticity in rats with temporal lobe epilepsy. *Brain Sci.* (2015) 15:747077. doi: 10.3398/ijnhum.2017.74077

83. Horvath A, Szucs A, Barcs G, Kondami A. Sleep EEG effects epileptiform activity in Alzheimer’s disease with high sensitivity. *J Alzheimers Dis.* (2017) 56:1175–83. doi: 10.3233/JAD-160994

84. Kanner AM, Helmstaedter C, Sadat-Hossiény Z, Meador K. Cognitive disorders in epilepsy I: clinical experience, real-world evidence and recommendations. *Seizure.* (2020) 83:216–22. doi: 10.1016/j.seizure.2020.09.009

85. Lehmann L, Lo A, Knox KM, Barker-Halils M. Alzheimer’s disease and epilepsy: a perspective on the opportunities for overlapping therapeutic innovation. *Neurochem Res.* (2021) 46:1895–912. doi: 10.1007/s11064-021-03332-y

86. Gimenez DeGeorge E, Fullen C, Gess J, Kleiner J, Larson-Prior L. Effects of age of onset and medication on cognitive performance and quality of life in patients with epilepsy. *Epilepsy Behav.* (2021) 121:108808. doi: 10.1016/j.yebeh.2021.108808

87. Carter MD, Weaver DE, Joadrey HR, Carter AO, Rockwood K. Epilepsy and antiepileptic drug use in elderly people as risk factors for dementia. *J Neurol Sci.* (2007) 252:169–72. doi: 10.1016/j.jns.2006.11.004

88. Sen A, Jette N, Husain M, Sander JW. Epilepsy in older people. *Lancet.* (2020) 395:735–48. doi: 10.1016/S0140-6736(19)33084-8

89. Pariente A, de Gage SB, Moore N, Begaud B. The benzodiazepine-dementia disorders link: current state of knowledge. *CNS Drugs.* (2016) 30:1–7. doi: 10.1007/s40263-015-0305-4

90. Billioti de Gage S, Moride Y, Ducruet T, Kurth T, Verdoux H, Tournier M, et al. Benzodiazepine use and risk of Alzheimer’s disease: case-control study. *BMJ.* (2014) 349:g5205. doi: 10.1136/bmj.g5205

91. Fleisher AS, Truran D, Mai JT, Langbaum JB, Asen PS, Cummings JL, et al. Chronic dipyridamole sodium use and brain atrophy in Alzheimer disease. *Neurology.* (2011) 77:1263–71. doi: 10.1212/01.wnl.0000381282.9816c

92. Arif H, Buchbaumer R, Pierro J, Whalen M, Sims J, Resor SR Jr, et al. Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. *Arch Neurol.* (2010) 67:408–15. doi: 10.1001/archneurol.2010.49

93. Lezaic N, Gore G, Josephson CB, Wiebe S, Jette N, Keezer MR. The medical treatment of epilepsy in the elderly: a systematic review and meta-analysis. *Epilepsia.* (2019) 60:1325–40. doi: 10.1111/epi.16068

94. Liu J, Wang LN. Treatment of epilepsy for people with Alzheimer’s disease. *Cochrane Database Syst Rev.* (2021) 5:CD011922. doi: 10.1002/14651858.CD011922.pub4

95. Gonzalez HG, Contreras-Garcia IJ, Sanchez-Huerta K, Queiroz CMT, Gallardo Gutino LI, Mendoza-Torreblanca JG, et al. Levetiracetam reduced the basal excitability of the dentate gyrus without restoring impaired synaptic plasticity in rats with temporal lobe epilepsy. *Brain Sci.* (2020) 10:634. doi: 10.3390/brainsci10090634

96. Vossel K, Ranasinghe KG, Beagle AJ, La A, Ah Pook M, Castro M, et al. Effect of levetiracetam on cognition in patients with Alzheimer disease with and without epileptiform activity: a randomized clinical trial. *JAMA Neurol.* (2021) 78:1345–54. doi: 10.1001/jamaneurol.2021.33110

97. Brodie MJ, Whitesides J, Schiemann J, D’Souza J, Johnson ME. Toleration, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: a pooled analysis from three phase III studies. *Epilepsy Res.* (2016) 127:114–8. doi: 10.1016/j.eplepsyres.2016.08.018

98. Ngaard HB, Kaufman AC, Sekine-Konno T, Huh HL, Gising H, Feldman SJ, et al. Brivaracetam, but not ethosuximide, reverses memory impairments in an Alzheimer’s disease mouse model. *Alzheimers Res Ther.* (2015) 7:25. doi: 10.1186/s13195-015-0110-9

99. Sarkis RA, Nicolai J, Lee JW. Toleration of lacosamide or zonisamide in elderly patients with seizures. *Seizure.* (2017) 49:1–4. doi: 10.1016/j.seizure.2017.04.010

100. Ahn SJ, Kim TJ, Cha KS, Jun JS, Byun JI, Shin YW, et al. Effects of perampanel on cognition and quantitative electroencephalography in patients with epilepsy. *Epilepsy Behav.* (2021) 115:107514. doi: 10.1016/j.yebeh.2020.107514

101. Lattanzi S, Cagnetti C, Foschi N, Giuffini R, Orsini E, Chiesa V, et al. Adjunctive perampanel in older patients with epilepsy: a multicenter study of clinical practice. *Drugs Aging.* (2021) 38:603–10. doi: 10.1007/s40266-021-00886-3

102. Rohracher A, Kalis G, Kuchukhidze G, Neuray C, Leitinger M, Holder J, et al. New anti-seizure medication for elderly epilepsy patients—A critical narrative review. *Expert Opin Pharmacother.* (2021) 22:621–34. doi: 10.1080/14656566.2020.1843636

103. Schoenberg MR, Ruim RS, Osborn KE, Werz MA. A randomized, double-blind, placebo-controlled crossover study of the effects of levetiracetam on cognition, mood, and balance in healthy older adults. *Epilepsia.* (2017) 58:1566–74. doi: 10.1111/epi.13849

104. Howard R, Zubko O, Bradley R, Harper E, Pank L, O’Brien J, et al. Minocycline at 2 different dosages vs placebo for patients with mild Alzheimer disease: a randomized clinical trial. *JAMA Neurol.* (2020) 77:164–74. doi: 10.1001/jamaneurol.2019.3762

105. Li KY, Huang LC, Chang YP, Yang YH. The effects of lacosamide on cognitive function and psychiatric profiles in patients with epilepsy. *Epilepsy Behav.* (2020) 113:107580. doi: 10.1016/j.yebeh.2020.107580

106. Iulgucci C, Iazzi F, Manfredi N, Mercuri NR, Piacidi F. Lacosamide may improve cognition in patients with focal epilepsy: epitrack to compare cognitive side effects of lacosamide and carbamazepine. *Epilepsia Behav Case Rep.* (2018) 10:36–7. doi: 10.1016/j.ebehr.2018.02.004

107. Lattanzi S, Canafoglia L, Canevini MP, Casciato S, Cerulli Irelli E, Chiesa V, et al. Adjunctive brivaracetam in older patients with focal seizures: evidence from the brivaracetam add on first italian network study (brivafrast). *Drugs Aging.* (2022) 39:297–304. doi: 10.1007/s40266-022-00931-4

108. Leppik IE, Wechsler RT, Williams B, Yang H, Zhou S, Laurenza A. Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase ii/iii epilepsy clinical trials. *Epilepsy Res.* (2015) 110:216–20. doi: 10.1016/j.eplepsyres.2014.11.015

109. Pohlmann-Eden B, Marson AG, Noack-Rink M, Ramirez F, Tofilgy A, Werhanh KJ, et al. Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded komet study. *BMJ Neurol.* (2016) 16:149. doi: 10.1136/bmjneurol-2016-01663-7

110. Musaeus CS, Shafi MM, Santarenchii E, Herman ST, Press DZ. Levetiracetam alters oscillatory connectivity in Alzheimer’s disease. *J Alzheimers Dis.* (2017) 58:1065–76. doi: 10.3233/JAD-160742